Viridian Therapeutics, Inc. VRDN Derivative, Gain (Loss) on Derivative, Net
Derivative, Gain (Loss) on Derivative, Net at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeGainLossOnDerivativeNet.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s derivative, gain (loss) on derivative, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s derivative, gain (loss) on derivative, net?
- Viridian Therapeutics, Inc. (VRDN) reported derivative, gain (loss) on derivative, net of $7.53M in Q1 2026.